PACS Group, Inc. (PACS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by PACS Group, Inc. and its officers for investors who purchased securities before April 11, 2024. The firm encourages these shareholders to contact them to learn more about the investigation and potentially assist in recovering investor capital. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis.
PACS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a detailed financial analysis of Pacs Group Inc (PACS), focusing on its revenue breakdown, profitability margins, and a comparison with competitors like CHE and BKD. PACS generates most of its revenue from Medicaid (38.1%), with a gross margin of 15.33% and a net margin of 4.40%. The company's financial health and market position are evaluated against industry benchmarks.
AI Investing Insights - Official Homepage - Intellectia AI™
This page from Intellectia AI™ provides detailed cash flow financial data for the stock PACS. It presents quarterly and yearly data for various cash flow metrics, including Net Cash Flow from Operating Activities, Funds from Operations, Net Cash Flow from Investing Activities, and Free Cash Flow, allowing users to analyze trends and make informed investment decisions. The platform also offers tools and resources for AI-driven investing.
The Technical Signals Behind (PACS) That Institutions Follow
This article analyzes Pacs Group Inc. (NASDAQ: PACS) using AI models to provide technical signals for institutional trading. It highlights divergent sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 29.1% gain. The piece outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis for near-term, mid-term, and long-term horizons.
Bronstein, Gewirtz & Grossman, LLC Is Investigating PACS Group, Inc. (PACS) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by PACS Group, Inc. (NYSE: PACS) and its officers/directors. The firm is encouraging investors who purchased PACS securities before April 11, 2024, and still hold them, to contact them to assist with the investigation. The investigation focuses on restoring investor capital and ensuring corporate accountability.
PACS Group price target lowered to $40 from $48 at Truist
Truist has reduced its price target for PACS Group (PACS) to $40 from $48. This adjustment reflects a revised outlook from the analyst firm regarding the company's valuation or future performance. The specific reasons for the price target change were not detailed in this short update.
PACS Group price target lowered to $40 from $48 at Truist
Truist has lowered its price target for PACS Group (PACS) shares from $48 to $40. This adjustment reflects a revised outlook from the analyst firm regarding the company's valuation or future performance trajectory.
Crewe Advisors LLC Has $82.46 Million Stock Holdings in PACS Group, Inc. $PACS
Crewe Advisors LLC significantly increased its stake in PACS Group, Inc. (NYSE:PACS) by 93.1% in Q4, now holding 2,147,815 shares valued at $82.46 million, making it their second-largest position. Despite a COO insider sale, analyst sentiment for PACS Group remains positive with a "Buy" consensus and an average target price of $44.40, following multiple price target upgrades from firms like RBC, UBS, and Oppenheimer. PACS Group operates skilled nursing and assisted living facilities, with strong insider ownership.
J.P. Morgan Maintains PACS Group(PACS.US) With Buy Rating, Maintains Target Price $44
J.P. Morgan has reiterated its Buy rating for PACS Group (PACS.US) and maintained its price target of $44. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.
Bronstein, Gewirtz & Grossman, LLC Encourages PACS Group, Inc. (PACS) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PACS Group, Inc. (NYSE:PACS) securities. The firm is encouraging stockholders who purchased PACS securities before April 11, 2024, and still hold them, to inquire about a possible securities investigation concerning corporate wrongdoing by PACS officers and/or directors. The firm operates on a contingency fee basis, meaning there is no cost to investors unless the firm is successful in its class action efforts.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PACS Group, Inc. (PACS) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into PACS Group, Inc. (PACS) regarding potential claims of corporate wrongdoing by its officers and/or directors. Investors who purchased PACS securities before April 11, 2024, and still hold them, are encouraged to join the investigation. The firm operates on a contingency fee basis, only seeking reimbursement if successful in recovering funds for investors.
PACS or MEDP: Which is the better value stock right now?
The article "PACS or MEDP: Which is the better value stock right now?" provides a comparative analysis of two stocks, PACS and MEDP, to determine which offers better value. It likely delves into various financial metrics, market positions, and future outlooks for both companies to help investors make an informed decision.
PACS Group (PACS) executive Mark Hancock awarded 98,154 RSUs in equity grant
Mark Hancock, a director and officer of PACS Group, Inc. (PACS), has been granted 98,154 restricted stock units (RSUs) as an equity award. These RSUs will vest in three equal annual installments starting March 24, 2026, contingent on his continued service. This grant is a compensation award and not a market purchase, and it represents a relatively small portion of his total holdings of over 54 million shares.
PACS Group, Inc. (NYSE:PACS) Receives Average Recommendation of "Buy" from Brokerages
PACS Group, Inc. (NYSE:PACS) has received an average "Buy" rating from six brokerages, with an average 1-year price target of $44.40. The company's shares opened at $32.33, trading below its 50-day moving average but above its 200-day moving average. Insider activity shows COO Joshua Jergensen recently sold 36,335 shares, though corporate insiders collectively own 70.40% of the company.
PACS Group Receives Consensus 'Buy' Rating from Analysts
PACS Group, Inc. (NYSE:PACS) has received a consensus 'Buy' rating from analysts, with an average 12-month price target of $44.40. This positive sentiment from Wall Street, including upgrades and 'Buy' ratings from firms like Wall Street Zen, Truist Financial, JPMorgan Chase, and UBS Group, suggests upside potential for the healthcare real estate company's stock. The company operates in the senior care and skilled nursing facility industries, and its stock has seen a 1-year high of $43.08.
PACS Group (PACS) 10K Form and Latest SEC Filings 2026
This article provides a comprehensive overview of PACS Group's (NYSE:PACS) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents, since 2024. It highlights the importance of these filings for investors to access verified financial data and track company activities. The article also details PACS Group's recent filings and offers a historical view of their submissions.
PACS Group (PACS) grants 82,039 RSUs to Chief Legal Officer
PACS Group, Inc. has granted 82,039 restricted stock units (RSUs) to its Chief Legal Officer and Secretary, John Todd Mitchell. These RSUs will vest in three equal annual installments beginning March 24, 2027, contingent upon his continued service. Following this grant, Mitchell directly holds 950,189 shares of the company's common stock.
PACS Group (PACS) HR chief receives 14,649 restricted stock units grant
PACS Group's Chief Human Resources Officer, Trent Dean Bingham, was granted 14,649 restricted stock units (RSUs) as equity compensation, increasing his directly held equity position to 39,649 shares/units. These RSUs convert to common stock upon vesting, which will occur in substantially equal annual installments on the first, second, and third anniversaries of March 24, 2026, contingent on his continued employment. This transaction highlights PACS Group's use of RSUs as part of its executive compensation strategy.
8,203 PACS Group (PACS) RSUs awarded to Chief Compliance Officer
PACS Group, Inc.'s Chief Compliance Officer, Kelly Priegnitz, received a grant of 8,203 restricted stock units (RSUs). These RSUs will vest in three equal annual installments beginning on March 24, 2026, and after this award, Priegnitz directly holds 38,203 shares of common stock. The transaction is categorized as a grant of shares, not an open-market purchase, and has a neutral impact and sentiment according to the filing summary.
PACS Group (PACS) awards 35,159 RSUs to Chief Accounting Officer Lewis
PACS Group, Inc. (PACS) has granted 35,159 restricted stock units (RSUs) to its Chief Accounting Officer, Michelle Renee Lewis. These RSUs will vest in three equal annual installments starting March 24, 2026, contingent on her continued employment. Following this award, Lewis directly holds 410,029 shares, including the new RSUs.
PACS or MEDP: Which is the better value stock right now?
This article poses a question comparing PACS and MEDP to determine which is currently the better value stock. Without further content, the article serves as an introduction to a deeper analysis of these two companies. It suggests a focus on investment value.
PACS Group (PACS) price target increased by 17.62% to 36.89
The price target for PACS Group (PACS) has been increased by 17.62% to $36.89. This adjustment reflects a significant positive outlook for the company's stock value.
Precision Trading with Pacs Group Inc. (PACS) Risk Zones
This article analyzes Pacs Group Inc. (PACS) using AI models, highlighting a weak near and mid-term sentiment despite a positive long-term outlook. It presents three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis points to an exceptional 74.2:1 risk-reward short setup.
PACS SEC Filings - PACS Group 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to PACS Group's SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries to help investors understand the regulatory documents. The article highlights recent filings concerning NYSE extensions due to delayed reports, the resignation and interim replacement of the CFO following policy findings, and an officer departure with a consulting agreement. It also provides current stock price and market capitalization data for PACS Group.
PACS Group Inc (PACS) Stock Price Down 3.61% on Mar 20
Shares of PACS Group Inc (PACS) fell by 3.61% on March 20, reaching an intraday low of $33.27 before closing at $33.39. This places the stock significantly above its 52-week low but below its 52-week high. Wall Street analysts have an average one-year target price of $41.67 for PACS, implying a 24.79% upside, with a consensus "Outperform" recommendation.
PACS SEC Filings - PACS Group 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of PACS Group's SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent significant filings such as insider stock awards, waivers for default events, and financial results for Q3 2025. The platform uses AI-powered summaries to help investors analyze PACS Group's regulatory disclosures and financial performance.
Joshua Jergensen Sells 36,335 Shares of PACS Group (NYSE:PACS) Stock
Joshua Jergensen, COO of PACS Group (NYSE:PACS), sold 36,335 shares of the company's stock on March 13th, 2026, for over $1.24 million, reducing his stake by 1.34%. Following the sale, he still holds over 2.6 million shares valued at approximately $91.4 million. The article also provides details on PACS Group's price performance, institutional trading, and recent analyst ratings, which largely maintain a "Buy" rating with an average target price of $44.40.
PACS Group (PACS) COO sells 36,335 shares around $34 level
PACS Group's President & COO, Joshua Jergensen, sold 36,335 shares of common stock on March 13, 2026, at a weighted average price of $34.2823 per share. The shares were sold in multiple trades ranging from $34.28 to $34.3301. Following this transaction, Jergensen directly owns 2,667,347 shares of PACS Group common stock.
PACS Group to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 17, 2026
PACS Group, Inc. announced its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 17, 2026. The company will present at the event, which focuses on trends in the healthcare technology and services sectors, sharing insights into its operations and advancements. Further details regarding the presentation's timing or format are currently undisclosed.
Jergensen Joshua, president & COO of PACS Group, sells $1.24 million in stock
Jergensen Joshua, President and COO of PACS Group, Inc. (NASDAQ:PACS), sold 36,335 shares of company stock worth $1.24 million on March 13, 2026. This sale follows a significant 191% gain in PACS stock over the past year and recent robust financial results for Q4 2025, which led to raised price targets from RBC Capital and Truist Securities. Despite the sale, Jergensen still directly owns over 2.6 million shares.
PACS: Record 2025 growth, strong financials, and robust M&A pipeline position the company for 2026
PACS Group, Inc. reported record growth in 2025, driven by a mission-focused model, high occupancy, and strong financials. Despite ongoing government investigations, the company's leadership highlighted operational strength, robust M&A opportunities, and provided optimistic guidance for 2026. This information is based on an AI-generated summary of their Oppenheimer 36th Annual Healthcare MedTech & Services Conference Audio Transcript.
Annual Healthcare MedTech & Services Conference on March 17, 2026
PACS Group, Inc. announced its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Tuesday, March 17, 2026. CEO Jason Murray and Interim CFO Mark Hancock will present on the company's operations and growth strategy. A live webcast and archived recording will be available for those unable to attend in person.
3 Medical Service Industry Stocks Set to Counter Workforce Issues
The Medical Services sector is rapidly evolving with digital health, value-based care, and patient-centric solutions driving growth, especially in telemedicine and AI-powered analytics. Despite projections of significant growth in healthcare analytics, the industry faces ongoing workforce shortages, with a projected deficit of 100,000 healthcare workers by 2028. This article highlights BrightSpring Health Services (BTSG), InnovAge (INNV), and PACS Group (PACS) as three Zacks #1 Rank (Strong Buy) stocks poised to benefit from these trends, showing strong earnings estimate revisions and competitive valuations.
A Look At PACS Group (PACS) Valuation After Record Earnings And Zacks Rank Upgrade
PACS Group (PACS) stock is under scrutiny following record earnings, improved margins, and a positive 2026 outlook. While a Simply Wall St narrative suggests the stock is 50% undervalued due to future profitability unlocked by integrating acquired facilities, another view highlights that its 28.6x P/E ratio is rich compared to the industry and peers, pointing to potential valuation risk. Investors are encouraged to assess these contrasting views and examine fundamental data, especially considering recent stock price cooling despite strong prior performance.
Does PACS Group’s (PACS) Optum CEO Board Addition Reframe Its Value-Based Care Ambitions?
PACS Group, Inc. recently appointed Patrick H. Conway, CEO of Optum and former CMS leader, to its Board of Directors. This strategic move could significantly influence PACS's approach to quality programs and reimbursement structures in post-acute and skilled nursing care, especially given Conway's expertise in value-based payment models. While this enhances governance, investors will need to monitor how the company executes on its new facilities and manages its reliance on state-level Medicaid and quality incentive schemes to meet its projected revenue and earnings targets.
Does PACS Group’s (PACS) Optum CEO Board Addition Reframe Its Value-Based Care Ambitions?
PACS Group, a healthcare services company, recently appointed Patrick H. Conway, CEO of Optum and former senior CMS leader, to its Board of Directors. This move is expected to sharpen the company's focus on quality and reimbursement innovation in post-acute and skilled nursing care, as Conway helped design major U.S. value-based payment models. The article suggests this appointment could influence how PACS Group approaches quality programs and reimbursement structures, adding to an investment narrative focused on converting acquired facilities into higher occupancy and margins.
Does PACS Group’s (PACS) Optum CEO Board Addition Reframe Its Value-Based Care Ambitions?
PACS Group, a post-acute and skilled nursing platform, recently appointed Patrick H. Conway, CEO of Optum and former CMS leader, to its Board of Directors. This move is expected to enhance PACS Group's focus on quality and reimbursement innovation, particularly concerning regulatory and payment risks in the healthcare sector. The company also provided 2026 revenue guidance of US$5.65 billion to US$5.75 billion, projecting significant growth by 2028.
PACS Group (NYSE:PACS) - Stock Analysis
This Simply Wall St report provides an in-depth stock analysis of PACS Group (NYSE:PACS), highlighting its market performance, financial health, and growth prospects. The company, which operates skilled nursing and assisted living facilities, shows strong earnings growth and positive analyst consensus for stock price increase. The report also includes recent news, historical stock prices, and comparisons with competitors in the US healthcare market.
PACS Group, Inc. (PACS) Raised to Strong Buy: The Reasons Explained
PACS Group, Inc. (PACS) has been elevated to a Zacks Rank #1 (Strong Buy) due to positive shifts in its earnings outlook, driven by improved earnings forecasts. This upgrade suggests strengthening business fundamentals and a potential for stock price increase, as the Zacks system has a strong track record of identifying outperforming stocks based on earnings estimate revisions. PACS Group is projected to earn $2.09 per share for the fiscal year ending December 2026, with analysts gradually raising estimates.
PACS Group, Inc. (PACS) Raised to Strong Buy: The Reasons Explained
PACS Group, Inc. (PACS) has been upgraded to a Zacks Rank #1 (Strong Buy) due to improved earnings forecasts, signaling a positive outlook for the company's stock. The Zacks rating system, which focuses on objective earnings data and estimate revisions, suggests that strengthening business fundamentals and investor interest could drive the stock higher. Historically, Zacks Rank #1 stocks have shown strong annual returns, making PACS a compelling candidate for potential near-term outperformance.
PACS Group, Inc. SEC Filing
This article reports on PACS Group, Inc.'s SEC Form 144 filing, which is a notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. The filing details the sale of 36,335 shares of common stock acquired through a restricted stock award on January 15, 2026, with an aggregate market value of $1,223,762.80, to be sold on the NYSE on March 9, 2026. The document includes filer and issuer information, securities details, and a representation that the selling party has no undisclosed material adverse information regarding the issuer.
PACS Group (NYSE:PACS) Upgraded by Zacks Research to "Strong-Buy" Rating
Zacks Research has upgraded PACS Group (NYSE:PACS) from a "hold" to a "strong-buy" rating. This upgrade is supported by a consensus "Buy" rating from analysts with an average target price of $44.40. The company has also seen a significant increase in institutional investment, with firms like Invesco and Janus Henderson substantially raising their stakes.
Pacs (PACS) Hits 52-Week High on Q3 Blowout
The article reports that Pacs (PACS) recently reached a 52-week high after reporting strong Q3 results. This surge indicates positive investor sentiment following the company's financial performance.
Optum chief Patrick Conway joins fast-growing post-acute care provider PACS
PACS Group, a rapidly growing post-acute healthcare platform, has appointed Dr. Patrick H. Conway, CEO of Optum and former CMS Deputy Administrator, to its Board of Directors. This strategic move aims to leverage Dr. Conway's deep expertise in clinical care, federal regulatory policy, value-based care, and healthcare innovation to navigate the evolving post-acute care landscape. His appointment is seen as transformative for PACS, providing unparalleled insight as the company continues its growth and leadership in the skilled nursing sector.
Bronstein, Gewirtz & Grossman, LLC Encourages PACS Group, Inc. (PACS) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PACS Group, Inc. (NYSE:PACS) securities. The firm encourages shareholders who bought PACS securities before April 11, 2024, and still hold them, to contact them to assist with the investigation. The investigation focuses on whether PACS, its officers, and/or directors engaged in corporate wrongdoing.
PACS vs. MEDP: Which Stock Is the Better Value Option?
This article analyzes whether PACS Group, Inc. (PACS) or Medpace (MEDP) is a better value option for investors in the Medical Services sector. Using the Zacks Rank and Value Style Scores, the article concludes that PACS is the superior option due to its Strong Buy rank, more impressive earnings estimate revision activity, and more attractive valuation metrics including P/E, PEG, and P/B ratios compared to MEDP.
Does PACS Group, Inc. (PACS) Have the Potential to Rally 25.45% as Wall Street Analysts Expect?
PACS Group, Inc. (PACS) closed at $36.35, and Wall Street analysts have set a mean price target of $45.6, indicating a potential upside of 25.5%. Despite the general unreliability of price targets, the strong agreement among analysts on upward revisions of earnings estimates for PACS, coupled with its Zacks Rank #1 (Strong Buy), suggests a legitimate reason for optimism regarding the stock's near-term performance. Investors are cautioned to treat price targets with skepticism but consider the positive earnings estimate trends as a stronger indicator.
A Look At PACS Group (PACS) Valuation After Record 2025 Results And New 2026 Guidance
PACS Group (NYSE:PACS) shares experienced a slight dip after announcing record 2025 results and new 2026 guidance, despite a strong 174% return over the past year. The market narrative suggests the stock is currently 3.9% overvalued with a fair value of $35, slightly below its current trading price of $36.35. Key challenges include reliance on state Medicaid frameworks and the operational strain of integrating over 100 recent acquisitions.
PACS Group (NYSE:PACS) Price Target Raised to $42.00 at Oppenheimer
Oppenheimer has increased its price target for PACS Group (NYSE:PACS) from $40.00 to $42.00, maintaining an "outperform" rating and implying a potential upside of 14.29% from its current price. Despite a recent stock dip, analysts collectively hold a "Moderate Buy" rating for PACS Group with an average target price of $44.00. Institutional investors have also been actively adjusting their holdings in the company.
PACS Group Inc (PACS) Shares Up 2.9% on Mar 4
Shares of PACS Group Inc (PACS) rose 2.9% in mid-day trading on March 4, closing at $37.94. This surge places the stock 11.93% below its 52-week high and 405.87% above its 52-week low. Wall Street analysts have an average target price of $41.00 for PACS, implying an 8.07% upside, with a consensus "Outperform" recommendation from six brokerage firms.
